Papain-like protease of SARS-CoV-2 inhibits dsRNA-induced type I interferon response partly by cleaving TBK1
- PMID: 40570639
- DOI: 10.1016/j.bbrc.2025.152244
Papain-like protease of SARS-CoV-2 inhibits dsRNA-induced type I interferon response partly by cleaving TBK1
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has claimed millions of lives and has been a global threat since its emergence. Multiple SARS-CoV-2-encoded proteins have been shown to exert interferon-I (IFN-I)-antagonizing effects, which contribute to severe pathogenesis. We previously reported that the papain-like protease (PLpro) of SARS-CoV-2 and SARS-CoV, a closely related highly pathogenic coronavirus, counteracts IFN production via its deubiquitinating (DUB) activity. In this study, we reveal a new mechanism by which SARS-CoV-2 negatively regulates host innate antiviral responses. Both PLpro proteins from SARS-CoV and SARS-CoV-2 mediated the proteolytic cleavage of TBK1, the hub kinase in the IFN-I signaling pathway. Using point mutants, we demonstrated that the catalytic triad, which is composed of C111, H272, and D286, and the enzyme activity regulatory site, W93, are essential for the ability of SARS-CoV-2 PLpro to cleave the TBK1 protein and for the inhibitory effect on TBK1-triggered IFN expression. However, the mutants failed to abrogate the suppressive effect of SARS-CoV PLpro on Sendai virus (SeV)-induced IFN-I promoter activation, indicating that PLpro inhibits the dsRNA-induced IFN response partly by cleaving TBK1. Collectively, our findings suggest a conserved mechanism through which highly pathogenic SARS-CoV and SARS-CoV-2 harness their PLpro proteins to suppress IFN expression at the level of TBK1, resulting in the evasion of the host innate antiviral response.
Keywords: Immune evasion; Papain-like protease; SARS-CoV-2; TBK1; Type I interferon.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no conflicts of interest with the contents of this article.
Similar articles
-
The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING.Sci Signal. 2023 May 2;16(783):eadd0082. doi: 10.1126/scisignal.add0082. Epub 2023 May 2. Sci Signal. 2023. PMID: 37130168
-
Regulation of N-degron recognin-mediated autophagy by the SARS-CoV-2 PLpro ubiquitin deconjugase.Autophagy. 2025 May;21(5):1019-1038. doi: 10.1080/15548627.2024.2442849. Epub 2025 Jan 2. Autophagy. 2025. PMID: 39723606 Free PMC article.
-
Discovery of SARS-CoV-2 papain-like protease inhibitors through machine learning and molecular simulation approaches.Drug Discov Ther. 2025 Jul 4;19(3):189-199. doi: 10.5582/ddt.2025.01034. Epub 2025 Jun 27. Drug Discov Ther. 2025. PMID: 40571587
-
Measures implemented in the school setting to contain the COVID-19 pandemic.Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 May 2;5:CD015029. doi: 10.1002/14651858.CD015029.pub2. PMID: 35037252 Free PMC article. Updated.
-
A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease.Neurotox Res. 2022 Oct;40(5):1553-1569. doi: 10.1007/s12640-022-00542-2. Epub 2022 Aug 2. Neurotox Res. 2022. PMID: 35917086 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous